Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis

  • Jorge Vila Arteaga
  • Mayerling Mercedes Suriano
  • Oana Stirbu
Case Report


The aim of this article is to report a case of Aspergillus chorioretinitis successfully treated with intravitreal voriconazole based on an interventional case report. An immunodeficient patient, 34 years old, receiving systemic antifungal treatment for 1 month for invasive aspergillosis with necrotizing pneumonia and brain metastasis, who presented with blurred vision in his left eye. Visual acuity (VA) was 20/20 in his right eye, and 8/20 in his left eye. Ophthalmological examination showed a paramacular nodular yellowish chorioretinal lesion with intraretinal hemorrhages, in the absence of vitritis or anterior uveitis. The patient was treated with one dose of intravitreal voriconazole (100 μg/0.1 ml). One week after the intravitreal injection, the patient’s VA was 10/20, the retinal lesions had diminished, and the hemorrhages had disappeared. At 3-month follow-up, his AV was 20/20 with a residual retinal scar. The significant and rapid improvement in this patient suggests that early injection of intravitreal voriconazole may be the first therapeutic option in Aspergillus chorioretinitis, obviating the need for vitrectomy.


Intravitreal Voriconazole Aspergillus Chorioretinitis 


  1. 1.
    Moorthy R, Davis J, Yen Lowder C et al (2009) Inflamación intraocular y uveitis. In: Liesegang T, Skuta G, Cantor L (eds) Curso de Ciencias Básicas y Clínicas. Elsevier Science, Spain, pp 250–251Google Scholar
  2. 2.
    Sen P, Gopal L, Ranjan P (2006) Intravitreal voriconazole for drug-resistant fungal endophthalmitis. Retina 26:935–939PubMedCrossRefGoogle Scholar
  3. 3.
    Groll A, Tragiannidis A (2010) Update on antifungal agents for paediatric patients. Clin Microbiol Infect 16:1343–1353. doi: 10.1111/j.1469-0691.2010.03334.x PubMedCrossRefGoogle Scholar
  4. 4.
    Herbrecht R (2004) Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti-infect Ther 2:485–497PubMedCrossRefGoogle Scholar
  5. 5.
    Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRefGoogle Scholar
  6. 6.
    Pfaller MA (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46:1032–1037PubMedCrossRefGoogle Scholar
  7. 7.
    Hariprasad SM, Mieler WF, Holz ER et al (2004) Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 122:42–47PubMedCrossRefGoogle Scholar
  8. 8.
    Kramer M, Kramer MR, Blau H et al (2006) Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 113:1184–1186PubMedCrossRefGoogle Scholar
  9. 9.
    Lin RC, Sanduja N, Hariprasad SM (2008) Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 24:245–248PubMedCrossRefGoogle Scholar
  10. 10.
    Thiel M, Zinkernagel AS, Burhenne J et al (2007) Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 51:239–244PubMedCrossRefGoogle Scholar
  11. 11.
    Hua G, Pennesi M, Shah K et al (2003) Safety of intravitreal voriconazole: electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc 101:183–189Google Scholar
  12. 12.
    Scott IU, Cruz-Villegas V, Flynn HW et al (2004) Delayed onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis. Am J Ophthalmol 137:583–585PubMedCrossRefGoogle Scholar
  13. 13.
    Bagnoud M, Baglivo E, Hengstlerl J et al (2001) Endogenous fungal endophthalmitis: results of antifungal treatment with and without vitrectomy. Klin Monbl Augenheilkd 218:398–400PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Jorge Vila Arteaga
    • 1
  • Mayerling Mercedes Suriano
    • 2
  • Oana Stirbu
    • 3
  1. 1.Ophthalmology ServiceHospital Clínico Universitario de ValenciaValenciaSpain
  2. 2.Ophthalmology ServiceHospital Clínico Universitario de ValenciaValenciaSpain
  3. 3.Ophthalmology ServiceHospital Clínico Universitario de ValenciaValenciaSpain

Personalised recommendations